- |||||||||| AST-05X / Aston Sci.
AST-05X: A novel GCN2 inhibitor as a promising anti-cancer approach for sarcoma (Section 22) - Mar 5, 2024 - Abstract #AACR2024AACR_3935;
In addition, based on the results of ISR-related gene expression profiling GEP analysis, we identified potential CDx biomarkers for evaluating the diagnosis and treatment response of sarcoma.Conclusion This study is currently investigating the efficacy of the drug in sarcoma patient-derived xenograft models. AST-05X is a GCN2 inhibitor that has the potential to validate the inhibition of GCN2 as a promising anti-cancer approach for sarcoma, a rare cancer with limited therapeutic alternatives.
|
